Product Launch

Project conducted by: Randy

Client: A Fortune 50 multinational pharmaceutical company 

Objective: Broadening the use of a point-of-care test – from emergency use authorization (EUA) to an in vitro diagnostic, submitting a 510K; the context was differentiating two communicable respiratory infections.

Randy performed economic and clinical outcome analyses on the client's data, and created value messaging for the three key stakeholders necessary for broad adoption– patients, healthcare providers, and payers. These analyses informed a nationwide product launch campaign.

Other Deliverables:

• HEOR-based pricing model

• Marketing collateral and storyboards

• Real-world evidence report

Outcome: Client proceeded in the advised direction and is on path to secure broad distribution and market acceptance (including coverage by commercial payers).